Schisandra

—

evidence score

adaptogen

Schisandra chinensiswu wei zifive-flavor berry+2 more

Schisandra chinensis is a traditional Chinese adaptogen known as "wu wei zi" (five-flavor berry) for its taste profile spanning all five TCM flavors. Its primary active compounds are schisandrins (lignans) and gomisins. Clinical evidence is strongest for liver protection (hepatoprotective, CYP enzyme modulation), physical and mental endurance in athletes, and adrenal stress response normalization. The adaptogenic effects are more subtle than ashwagandha or rhodiola but it offers a unique combination of performance + liver health that makes it valuable in any stack using hepatically-metabolized compounds.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Research Sync

Not synced yet

Dosing

Typical

1000 mg

500 mgRange3000 mg

Frequency1-2x/day

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~4-6 hours

OnsetPerformance effects 1-2 weeks; liver enzyme normalization 4-8 weeks

DurationOngoing with daily use

Routes

oral

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(40%)—

Quality(30%)—

Sample Size(10%)—

Consistency(10%)—

Replication(5%)—

Recency(5%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Schisandra is currently categorized as a adaptogen compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Schisandrins modulate NF-kB and Nrf2 pathways; induce CYP3A4/CYP2C19; hepatoprotective via antioxidant induction; HPA axis normalization

Practical Context

Strongest current signals

No indexed study summaries yet.